Baxter, Nycomed sales and marketing update

Baxter disclosed in its 3Q10 earnings that it launched TachoSil in the U.S. as an adjunct to hemostasis in cardiovascular surgery. Nycomed granted Baxter exclusive U.S. marketing rights to the human ...